Monoclonal antibodies and autologous stem cell transplantation for lymphoma

被引：10

作者：

Flinn, IW

Lazarus, HM

机构：

[1] Johns Hopkins Oncol Ctr, Div Hematol Malignancies, Baltimore, MD 21231 USA

[2] Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA

来源：

BONE MARROW TRANSPLANTATION | 2001年 / 27卷 / 06期

关键词：

transplantation; monoclonal antibody; lymphoma;

D O I：

10.1038/sj.bmt.1702857

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

The introduction of monoclonal antibodies into the clinic has paved the way for new approaches to stem cell transplantation for patients with lymphoma. These approaches include the development of new high-dose regimens with radiolabeled antibodies, in vivo purging techniques with the unlabeled antibodies, and posttransplant adjuvant immunotherapy. Numerous trials have demonstrated the feasibility of these approaches. However, questions remain regarding the application of these antibodies including the ultimate efficacy. The recent results of the incorporation of monoclonal antibodies into stem cell transplantation and current research directions are reviewed.

引用

页码：565 / 569

页数：5

共 27 条

[1] YTTRIUM-90-LABELED ANTIFERRITIN FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR POOR-PROGNOSIS HODGKINS-DISEASE [J].

BIERMAN, PJ ;

VOSE, JM ;

LEICHNER, PK ;

QUADRI, SM ;

ARMITAGE, JO ;

KLEIN, JL ;

ABRAMS, RA ;

DICKE, KA ;

VRIESENDORP, HM .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :698-703

[2]

BIERMAN PJ, 2001, P 10 INT S ARL TEX

[3] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy [J].

Czuczman, MS ;

Grillo-López, AJ ;

White, CA ;

Saleh, M ;

Gordon, L ;

LoBuglio, AF ;

Jonas, C ;

Klippenstein, D ;

Dallaire, B ;

Varns, C .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :268-276

[4] Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs [J].

Demidem, A ;

Lam, T ;

Alas, S ;

Hariharan, K ;

Hanna, N ;

Bonavida, B .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (03) :177-186

[5] In vivo 'purging' of residual disease in CLL with Campath-1H [J].

Dyer, MJS ;

Kelsey, SM ;

Mackay, HJ ;

Emmett, E ;

Thornton, P ;

Hale, G ;

Waldmann, H ;

Newland, AC ;

Catovsky, D .

BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (03) :669-672

[6] Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma [J].

Flinn, IW ;

O'Donnell, PV ;

Goodrich, A ;

Vogelsang, G ;

Abrams, R ;

Noga, S ;

Marcellus, D ;

Borowitz, M ;

Jones, R ;

Ambinder, RF .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (06) :628-632

[7] Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma [J].

Freedman, AS ;

Neuberg, D ;

Mauch, P ;

Soiffer, RJ ;

Anderson, KC ;

Fisher, DC ;

Schlossman, R ;

Alyea, EP ;

Takvorian, T ;

Jallow, H ;

Kuhlman, C ;

Ritz, J ;

Nader, LM ;

Gribben, JG .

BLOOD, 1999, 94 (10) :3325-3333

[8]

Golay J, 2000, BLOOD, V95, P3900

[9] IMMUNOLOGICAL PURGING OF MARROW ASSESSED BY PCR BEFORE AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR B-CELL LYMPHOMA [J].

GRIBBEN, JG ;

FREEDMAN, AS ;

NEUBERG, D ;

ROY, DC ;

BLAKE, KW ;

WOO, SD ;

GROSSBARD, ML ;

RABINOWE, SN ;

CORAL, F ;

FREEMAN, GJ ;

RITZ, J ;

NADLER, LM .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (22) :1525-1533

[10] THE CAMPATH-1 ANTIGEN (CDW52) [J].

HALE, G ;

XIA, MQ ;

TIGHE, HP ;

DYER, MJS ;

WALDMANN, H .

TISSUE ANTIGENS, 1990, 35 (03) :118-127

← 1 2 3 →